Fungi represent a significant proportion of the gut microbiota, but how anti-fungal immunity contributes to tumor-promoting inflammatory responses is unclear. Malik et al. find that recognition of commensal gut fungi, sensed via the Card9-Syk signaling axis, is protective in the context of inflammation-associated cancer. IL-18 maturation downstream of inflammasome activation promotes epithelial barrier restitution and IFN-g production by intestinal CD8 + T cells.
INTRODUCTION
Crohn's disease (CD) and ulcerative colitis (UC) are common inflammatory bowel diseases (IBD) that together affect more than 3 million individuals in the United States of America, constituting a major health crisis (Dahlhamer et al., 2016) . IBD is characterized by chronic inflammation in the intestine with episodic abdominal pain, diarrhea, rectal bleeding, and body weight loss (Kappelman et al., 2013) . Mucus and epithelium form a physical barrier between the commensal microbes and the underlying host immune system, and deterioration of this barrier is prominent in IBD patients (Podolsky and Isselbacher, 1984; Rhodes, 1996) . IBD also increases the risk of developing colorectal cancer (CRC) (Grivennikov et al., 2010) . CRC is a leading cause of cancer-related deaths in adults, with 160,000 cases being diagnosed annually in the USA, and inflammation is associated with approximately 90% of these cases (Howlader et al., 2015) . We and others have shown that gut bacteria modulates IBD and CRC pathogenesis (Elinav et al., 2011; Malik et al., 2016; Man et al., 2015) . Fungi are also a significant component of the gut microbiota and IBD patients develop increased titers of anti-fungal antibodies, suggesting a role for fungi in the pathogenesis of these diseases (McKenzie et al., 1990) . Fungal diversity in stool samples from UC patients is significantly decreased when compared with healthy controls (Sokol et al., 2017) . In line with decreased fungal diversity during IBD in humans, fungal diversity also narrows during DSS-induced colitis in mice (Qiu et al., 2015) . Further, deficiency in the fungal recognition C-Type Lectin Receptors (CLRs) Dectin-1, Dectin-3, or a common downstream signaling adaptor Caspase recruitment domain 9 (CARD9) are reported to increase severity of DSSinduced colitis in mice (Iliev et al., 2012; Lamas et al., 2016; Sokol et al., 2013) . In contrast to these studies, CARD9 was shown to promote colitis-associated cancer by regulating IL-22 production from group 3 innate lymphoid cells (Bergmann et al., 2017) . Whereas anti-fungal treatment ameliorates colitis in Dectin-1-deficient mice, it exacerbates colitis in wild-type mice (Wheeler et al., 2016) . Mutations in CARD9 are highly associated with increased susceptibility to both fungal infections and IBD in humans (Glocker et al., 2009; Zhernakova et al., 2008) . These reports suggest that interaction of commensal gut fungi with the mucosal immune system can modulate IBD. Moreover, mycobial diversity during colon tumorigenesis in humans is also decreased (Luan et al., 2015) . However, the role of gut fungi or associated immune sensing pathways in tumorigenesis has not been explored.
Inflammasomes are multimeric protein complexes that form upon sensing of a diverse range of pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). The inflammasome forms a platform to activate the cysteine protease caspase-1, which triggers the proteolytic processing of cytokines, interleukin (IL)-1b, and IL-18, and induces pyroptosis, a form of cell death . Inflammasome-forming receptors are cytosolic sensors that include nucleotide-binding oligomerization domain-like receptors (NLRs) and absent in melanoma (AIM2)-like receptors (ALRs). Mutations in genes that encode components of the inflammasome are frequently associated with auto-inflammatory diseases and cancer (Karki et al., 2017; Zhang et al., 2015) . NLRP1 (Williams et al., 2015) , NLRP3 (Allen et al., 2010; Zaki et al., 2010a) , NLRC4 (Carvalho et al., 2012; Hu et al., 2010) , Pyrin (Sharma et al., , 2018 , NLRP6 (Chen et al., 2011; Elinav et al., 2011) , and IL-18 have been shown to modulate colitis and colon tumorigenesis . We and others have shown that fungi are potent inducers of the inflammasome Lamkanfi et al., 2009 ). However, the relative contribution of the components of fungal-sensing pathways including CARD9 and its upstream activator spleen tyrosine kinase (SYK) in modulating inflammasome activation and gut homeostasis has not been explored in detail.
Here we found that commensal gut fungi signal via the SYK-CARD9 pathway to restrain colitis and colorectal cancer. Commensal gut fungi contributed to inflammasome activation and IL-18 maturation during colitis. Early IL-18 maturation by inflammasome promoted epithelial barrier restitution and interferon gamma (IFN-g) production from the CD8 + T cells. Mice lacking CARD9 and SYK were similarly defective in inflammasome activation and susceptible to colitis and colorectal cancer. Consequently, colitis and tumor-promoting inflammation in these mice was reduced by supplementation with IL-18 or by transfer of myeloid cells capable of inflammasome activation after fungal recognition. These findings reveal a role for commensal fungi and the associated signaling cascade in restraining colitis and colon cancer by promoting inflammasome activation.
RESULTS

CARD9 Restrains Colitis and Colorectal Cancer
Because mycobial diversity and mutations in CARD9 are associated with IBD and colon tumorigenesis in humans (Glocker et al., 2009; Zhernakova et al., 2008) , we sought to further explore the function of CARD9 in colitis and CRC. Expression of CARD9 was detectable in colon tissues from healthy humans and was increased in colon tumor biopsies in the GENT database (Figure 1A ; Shin et al., 2011 Figures S1A and S1B ). Immunofluorescence analysis showed increased staining for CARD9 at day 14, which was distinct from EpCAM + cells ( Figure S1C ). Immunohistochemical staining of CARD9 in human colon biopsies cataloged in the human protein atlas (Uhlé n et al., 2015) also demonstrated positively stained cells to be restricted to the lamina propria ( Figure S1D ). Increased expression of CARD9 in human colon tumor tissue, compared with the normal control tissue, also correlated with the increased expression of the myeloid cell marker, ITGAM (CD11b) (Figure S1E) . Therefore, the expression of CARD9 in the colon is increased in the immune cells during colon tumorigenesis.
To evaluate the role of CARD9 in colitis and colon cancer, we subjected WT and Card9 À/À mice that were separated upon weaning (3-4 weeks old) to AOM-DSS treatment ( Figure S1F ). Compared to WT mice, Card9 À/À mice lost more body weight during DSS treatment ( Figure 1E ). At day 80, colons of Card9
mice exhibited increased number of tumors in the distal (bottom 1/3 rd ) and middle (central 1/3 rd ) region that were also bigger in size when compared to the WT mice ( Figures 1F-1H ). Histological analysis revealed greater extent of inflammation and epithelial hyperplasia in Card9 À/À colons ( Figures 1I-1K ).
Splenomegaly, an indicator of systemic inflammation, was also significantly enhanced in Card9 À/À mice ( Figure 1L ). Whereas the numbers of B cells, CD4 + T cells, and CD8 + T cells were similar between the spleens of WT and Card9 À/À mice, the numbers of macrophages, neutrophils, and monocytes was significantly increased ( Figure 1M ). Colitis is a predisposing factor for tumorigenesis (Grivennikov et al., 2010) . Similar to the observations during tumorigenesis, expression of both CARD9 mRNA and protein were increased in the colon tissue during acute colitis (day 14) (Figures 2A-2C ). Day 14 was considered a time point for acute colitis because on day 14, mice typically display significant body weight loss, colon shortening, and histological manifestations of colitis, without the presence of macroscopic tumors ( Figures  2D-2G ). To determine the role of CARD9 in acute colitis, WT and Card9 À/À mice were injected with AOM and subjected to a single round of DSS in drinking water. Consistent with the previous data ( Figure 1E ), Card9 À/À mice lost significantly more body weight when compared to WT mice ( Figure 2D ). At day 14, Card9 À/À mice also had significantly shorter colons (Figures 2E and 2F), a characteristic of acute colitis (Gaudio et al., 1999) . Histological analysis revealed significant increase in inflammation, ulceration, and extent of lesions in the colons of the Card9
mice when compared to WT mice ( Figures 2G and 2H ). Increased colitis in Card9 À/À mice was also associated with decreased IFN-g and TNF production from CD4 + T and CD8 + T cells ( Figure 2I ). Thus, signaling via CARD9 limits inflammation and inflammation-associated cancer in the AOM-DSS model.
CARD9 Promotes Inflammasome Activation in the Colon
To ascertain the immunological basis of increased colitis and colon cancer in Card9 À/À mice, the immune response was assessed at days 9 and 14 after AOM injection. IL-18 secretion was significantly decreased in the Card9 À/À colon explants, both on day 9 and day 14, compared to the WT explants (Figure 3A) . While there was no difference in the release of G-CSF, KC, or IL-6 at day 9, these cytokines were increased in the colons and sera of Card9 À/À mice at day 14 ( Figure 3A ). Concentration of MCP-1 was also increased in the sera on day 14 ( Figure 3A ). Expression of Il22 and its associated anti-microbial peptides (AMPs) Reg3g and Reg3b were also unperturbed at day 9 post-AOM ( Figure 3B ). There were no significant differences in the expression of goblet cell differentiation factors Klf4 and Spdef or the major colon mucin Muc2 at basal or pre-clinical time between WT and Card9 À/À colons ( Figure S2A ). Consistently, activation of ERK1, ERK2, and NF-kB were similar at day 9 but increased at day 14 in the Card9 À/À colons, while phosphorylation of MAPKs p38 and JNK was comparable (Figures 3C and S2B) . Activation of STAT3, a major driver of colon tumorigenesis (Grivennikov et al., 2009) , was also increased in the colons of the Card9 À/À mice ( Figures 3C and S2B ). Therefore, reduced IL-18 secretion precedes the enhanced inflammatory response observed in colons of Card9 À/À mice.
The decrease in IL-18 release was independent of transcriptional regulation because expression of Il18 and the decoy receptor Il18bp were similar in colons of Card9 À/À and WT mice ( Figure 3D ). The proportion of CD11b + cells ( Figure S2C ) and the expression of Il18 in the CD11b + cells ( Figure S2D ) of the colon, MLN, and spleen were also similar between WT and Card9 À/À mice. The decrease in IL-18 secretion was due to lower activation of caspase-1, as evidenced by reduced caspase-1 activation in the colon tissue of Card9 À/À mice (Figures 3E and S2B) at both day 9 and day 14. These findings demonstrate that CARD9 is required to promote inflammasome activation and optimum IL-18 maturation in the colon during colitis and colon cancer. Figure 4L ). Therefore, deficiency of Caspase-1 does not hinder the survival or migration of myeloid cells during adoptive transfer. Taken together, these findings demonstrate that CARD9 promotes inflammasome activation and subsequent IL-18 maturation in the colon and that this alleviates colitis and associated epithelial hyperplasia in the AOM-DSS model.
IL-18 Production by Myeloid Cells Restricts Colitis in
Card9
-/-Mice Exhibit Altered Microbial Landscape CARD9 regulates the gut fungal and bacterial microbiota (Lamas et al., 2016) . IL-18 promotes a symbiotic gut microbiota such that WT mice that are cohoused with the Il18 À/À mice during AOM-DSS administration have more severe colitis (Levy et al., 2015) . To test whether the CARD9-IL-18 axis similarly affected the gut microbiota and the susceptibility to colitis and colorectal cancer, we cohoused the WT and Card9 À/À mice during AOM-DSS treatment. WT mice housed with Card9 À/À mice throughout the AOM-DSS treatment displayed increased weight loss and colon shortening at day 14 and a higher colonic tumor burden on day 80, as compared to WT mice housed separately ( Figures S3A-S3F ). The cohoused WT and Card9 À/À mice showed similar extent of body weight loss, colon shortening, and overall number of tumors in the colon. However, the cohoused WT mice developed significantly more number of tumors in the distal colon as compared to the Card9 À/À mice ( Figures S3A-S3F ), in line with recent observations (Bergmann et al., 2017) .
(I) Flow-cytometric analysis for TNF-a and IFN-g production from CD8 + and CD4 + T cells from colonic epithelial, lamina propria fractions, and mesenteric lymph nodes and spleens of WT and Card9 À/À mice.
Each symbol represents an individual mouse. NS, not significant; *p < 0.05; **p < 0.01, ***p < 0.001; Mann-Whitney U test (B and I), two-way ANOVA followed by the Holm-Sidak post hoc test (D, E, and H), or one-way ANOVA followed by the Holm-Sidak post hoc test (C). Data are from one experiment representative of two independent experiments with n = 5-8 mice per group (A-H; mean and SEM [B-E, H, and I]). To directly test whether cohousing led to normalization of the gut microbiota between the WT and Card9 À/À mice, we characterized the fungal and bacterial diversity in WT, Card9 Figure S4 ). While cohousing normalized the composition of the bacteria, the abundance of Phormidiaceae and alphaproteobacteria RF32 was lower while Mycoplasmataceae was higher in the Card9 À/À mice housed with the WT mice. Taken together, these data show that CARD9 controls the gut mycobial and bacterial landscape and that the deficiency of CARD9 can transfer the increased susceptibility to the cohoused WT mice.
CARD9 Interacting Partner SYK Is Required for Protection from Colitis and Colon Cancer
We next explored the upstream pathways involved in CARD9-mediated inflammasome activation during colitis and CRC. Activation of SYK is a common link between CLRs and downstream CARD9 activation Ruland, 2008) . Further, SYK activation (phosphorylation) was detectable in mouse colons under homeostatic conditions (day 0) and substantially increased in colons from inflamed (day 14) and tumor-bearing (day 80) mice ( Figure 5A ). Mice with global deficiency in SYK die in the perinatal stage (Cheng et al., 1995) Figure 5C ). At day 80, Syk LysM mice exhibited an increased number of tumors that were also bigger in size when compared to WT mice ( Figures 5D-5F ). Histological analysis revealed greater extent of inflammation and epithelial hyperplasia in colons (Figures 5G and 5H) and splenomegaly ( Figures 5I and 5J ). These findings are in line with Card9 À/À mice and demonstrate that SYK-CARD9 function in myeloid cells protects from colon cancer. Further, Syk LysM mice also displayed characteristics of acute colitis-increased weight loss, disease activity, and colon shortening at day 15 when compared to WT mice ( Figures 5K-5N) . Histological analysis of the colons at day 15 also demonstrated increased inflammation, ulceration, edema, and extent of lesions in Syk LysM mice ( Figures 5O and 5P ). IL-18 was significantly decreased in the colon and serum at preclinical time (day 9), demonstrating a critical role of SYK-CARD9 axis in promoting inflammasome activation early during disease pathogenesis (Figure 5Q ). These findings demonstrate that both SYK and CARD9 are required to promote inflammasome activation and optimum IL-18 maturation in the colon during colitis and colon cancer. We also confirmed a significant role for SYK and CARD9 in caspase-1 activation and IL-18 maturation in bone marrowderived myeloid cells after stimulation with fungi ex vivo. SYK and CARD9 were required for caspase-1 activation and IL-18 release in response to stimulation with Candida albicans ( Figures  S5A and S5B ). Canonical and non-canonical NLRP3 activation triggered by LPS+ATP and intracellular LPS, respectively, was unaffected by loss of SYK or CARD9 (Figures S5C and S5D ). SYK and CARD9 also did not affect AIM2 or NLRC4 inflammasome activation after DNA transfection or Salmonella infection, respectively ( Figures S5E and S5F) . Therefore, CARD9 and (legend continued on next page) SYK are specifically required for inflammasome activation in myeloid cells in response to fungal stimuli.
Commensal Fungi Are Major Inducers of Inflammasome Activation in the Colon
Fungi and anaerobic bacteria are major components of the gut microbiota, especially in the distal colon where inflammation and tumors are most evident with AOM-DSS treatment (Donaldson et al., 2016) . To determine the relative contribution of fungi in provoking inflammasome activation during AOM-DSS treatment, mice were depleted of commensal fungi by treatment with amphotericin B (AmpB) or Itraconazole (Itra) orally for 4 weeks prior to AOM-DSS administration. Treatment with AmpB led to a significant decrease in the total fungal loads (Figures 6A and S6) . We further characterized the fungal and bacterial diversity in mice treated with AmpB or Itra by 18S ITS and 16S rRNA sequencing. Principal coordinate analysis based on the Bray-Curtis dissimilarity of the genus composition revealed that amphotericin B or itraconazole treatment led to a similar shift in the mycobial landscape, when compared to the water-treated group ( Figure S6A ). Treatment of mice with AmpB or Itra led to a significant decrease in several members of Ascomycota, particularly the Leotiomycetes, Helotiales, and Pseudocercospora (Dothideomycetes) ( Figure S6B ). 16S rRNA analysis, however, revealed a distinct bacterial landscape in mice treated with AmpB or Itra ( Figure S6C ). In the AmpB-treated mice, the members of Bacteroidetes including Prevotellaceae, Rikenellaceae, and Bacteroidaceae were increased, while Opitutae (Verrucomicrobia), Phormidiaceae (Cyanobacteria), and Bifidobacteriaceae (Actinobacteria) were decreased (Table S2 ). For the Itra-treated mice, significantly increased Prevotellaceae and RF16 of Bacteroidales were observed, while the occurrence of Alcaligenaceae (Proteobacteria), Ruminococcus (Firmicutes), Helicobacteraceae (Proteobacteria), and several other members of Firmicutes were decreased (Table S3) . Therefore, treatment of mice with AmpB or Itra leads to similar depletion of commensal fungi, but distinct changes in the bacterial landscape. Upon treatment with a low dose (2%) of DSS, mice treated with AmpB lost significantly more body weight, displayed increased signs of disease, and had shorter colons on day 14 ( Figures 6B-6E ), indicating that commensal fungi are protective against acute colitis. Consistent with the role of molecules involved in fungal sensing, depletion of fungi also led to decreased release of inflammasome-associated cytokine IL-18 ( Figure 6F ) and decreased transcription of Ifng early during AOM-DSS treatment ( Figure 6G ). Similar results were obtained when commensal fungi were depleted in WT mice by Itraconazole ( Figures 6H-6J) . Further, depletion of commensal fungi in the Card9 À/À mice by treatment with Itraconazole did not affect the susceptibility to AOM-DSS-induced colitis or secretion of IL-18 from the colon explants ( Figures 6H-6J) . Therefore, commensal fungi in the gut promote inflammasome activation to protect from colitis in a CARD9-dependent manner.
To directly test whether increased inflammation in mice depleted of fungi was due to decreased IL-18 release, we supplemented AmpB-pretreated mice with exogenous IL-18 during AOM-DSS treatment. Supplementation with IL-18 was able to significantly protect the AmpB-treated mice from exacerbated weight loss and colon shortening (Figures 6K and 6L) . IL-18 supplementation also restored the IFN-g production from CD8 + T cells in the mesenteric lymph nodes ( Figure 6M ). Histological analysis of the colon further revealed significant increases in inflammation, ulceration, edema, and the extent of lesions in AmpB-treated mice, which were ameliorated by supplementation with IL-18 ( Figures 6N and 6O) .
In sharp contrast, depletion of anaerobic bacteria by Mtz treatment led to a significant increase in the overall fungal loads while depleting anaerobic bacteria, including Prevotella ( Figures 6P,  S9A , and S9B). We further characterized the bacterial and fungal microbiota by 16S rRNA and 18S ITS sequencing. PCoA analysis of the bacterial and fungal composition at the genus level revealed that mice given Mtz formed an independent group (Figures S7A and S7B ). 16S analyses of the bacterial taxa demonstrated significant decrease in the occurrence of Rikenellaceae and S24_7 of Bacteroidales, Deferribacteraceae, and Alphaproteobacteria and increase in Lactobacillaceae, Enterobacteriaceae, Mycoplasmataceae, Aerococcaceae, and Porphyromonadaceae ( Figure S7C ), while the 18S analysis revealed an increase in an unassigned group. Upon AOM-DSS treatment, Mtz-treated mice were significantly protected from signs of acute colitis including body weight loss, colon shortening, and associated histological perturbations ( Figures 6Q-6T ). Therefore, AmpB-or Itra-sensitive commensal fungi promote inflammasome activation and protect from colitis, while Mtz-sensitive commensal anaerobes promote colitis.
Commensal Fungi-SYK-CARD9-IL-18 Axis Is Protective from Colon Cancer
To directly test whether the loss of IL-18 is also responsible for the increased tumorigenesis in the colons of Card9 À/À and Syk (legend continued on next page) treatment, when compared to the Card9 À/À or Il18 À/À mice given control injections during AOM-DSS treatment ( Figures 7A-7C ). Exogenous IL-18 treatment in WT mice also led to a decrease in the number of tumors in the colon (Figures 7A-7C ). Similar to the observations in the Card9 À/À mice, exogenous IL-18 supplementation during AOM-DSS treatment also protected the Syk LysM mice from the exacerbated weight loss and colon tumorigenesis ( Figures 7D-7F ).
To test whether commensal fungi play an active role in the pathogenesis of colitis-associated colon cancer, we depleted WT mice of commensal fungi (with AmpB treatment) or anaerobic bacteria (with Mtz treatment) or both (simultaneous AmpB and Mtz treatment) before AOM-DSS treatment. Similar to our observations with the Card9 À/À and Syk LysM mice, AmpB treatment increased the extent of body weight loss and colon tumorigenesis upon AOM-DSS administration, which was also ameliorated significantly by exogenous IL-18 supplementation ( Figures 7G-7I ). On the other hand, Mtz treatment ameliorated the body weight loss and colon tumor burden ( Figures 7J-7L ). To test whether the protection conferred by Mtz was due to the increase in fungal loads, we simultaneously depleted both commensal fungi and anaerobic bacteria by simultaneous Mtz and AmpB administration. Mice receiving both Mtz and AmpB had exacerbated body weight loss and colon tumorigenesis when compared to mice receiving Mtz alone, demonstrating an active role for commensal fungi in suppressing colitis-associated colon cancer ( Figures 7J-7L) . Therefore, commensal fungi-SYK-CARD9 axis is protective from colitis-associated colon cancer, at least in part, by prompting inflammasome activation and IL-18 maturation in the colon.
DISCUSSION
Currently available anti-TNF biologics provide sustained disease remission in only 25% of IBD patients, while another 30% require total colectomy (Nielsen, 2014) . IBD is also a strong predisposing factor for CRC, a leading cause of cancer-related death in adults (Howlader et al., 2015) . While the etiology of IBD is unknown, aberrant immune responses to commensal microbes are widely thought to underlie it. Therefore, the role of specific components of the microbiota, and associated signaling pathways that regulate disease susceptibility, are avenues of active research. Inflammasome activation is one such critical aspect of innate immunity that has been shown to modulate colitis and CRC pathogenesis . In this study, we demonstrate that commensal gut fungi signaling via SYK-CARD9 axis is essential for IL-18 maturation and protection from experimental colitis and CRC.
SYK-CARD9 signaling axis is activated downstream of CLRs and has been shown to induce NF-kB, ERK, p38 MAPK, and JNK signaling and cytokine production during fungal infection Ruland, 2008) . SYK and CARD9 are also required for inflammasome activation by Candida and Aspergillus (Gringhuis et al., 2012) . We found that colons of Card9 À/À mice did not exhibit any defects in expression of cytokines or chemokines, or NF-kB, ERK, p38 MAPK, and JNK signaling early during experimental colitis. Consistent with increased inflammation and epithelial hyperplasia during acute disease, ERK, IkBa, and STAT-3 phosphorylation were increased during acute disease. In contrast, inflammasome activation and IL-18 secretion were significantly lower in colons of Card9 À/À and Syk LysM mice and mice depleted of commensal gut fungi prior to clinical disease. IL-18 is known to be a limiting factor in IFN-g production in the colon (Salcedo et al., 2010) and in line with our observations of defective IL-18 secretion in colons from Card9 À/À mice, they also have lower production of IFN-g from T cells during experimental colitis. Further, IL-18 supplementation was able to significantly ameliorate colitis and CRC and promote IFN-g production from T cells. Therefore, commensal fungi are a critical contributor to inflammasome activation via the SYK-CARD9 pathway, and IL-18 production downstream of the inflammasome is required for maximal IFN-g production from T cells. Further studies will be needed to determine whether the IFN-gproducing CD8 + T cells are specific to the antigens presented by the colon tumors and directly mediate anti-tumor immunity and to elucidate the cell-type-specific contribution of CARD9 in promoting inflammasome activation in the colon. Further, treatment with two different anti-fungal agents led to a similar shift in the mycobial landscape but distinct changes in the bacterial landscape. This suggests that increased susceptibility observed with these anti-fungal agents is likely attributable to depletion of fungi and not to the changes in the bacterial microbiome. Nevertheless, it is possible that fungal depletion leads to an overall ecological shift that favors lower inflammasome activation and increased colitis and colon cancer. Therefore, commensal fungi may have an indirect role in protecting from colitis and CRC as well. IL-18 and inflammasomes play multifaceted roles in colitis and colon cancer. Expression of IL-18 and the accessory protein IL-18RAP are lower in human colon cancer biopsies, and polymorphisms in the components of the IL-18 signaling pathway are associated with increased susceptibility to IBD in humans (Barrett et al., 2008; Hedl et al., 2014) . Mice lacking IL-18 or the inflammasome components such as Nlrp3 (legend continued on next page) Salcedo et al., 2010; Zaki et al., 2010a Zaki et al., , 2010b . However, excessive inflammasome activation and loss of the IL-18 decoy receptor increase the susceptibility to experimental colitis (Neudecker et al., 2017; Nowarski et al., 2015) . Therefore, both the lack and excess of inflammasome activation and IL-18 can promote inflammation in the colon (Mager et al., 2016; . Mucosal IL-18 responses have also been implicated in governing a transmissible gut microbiota (Levy et al., 2015) . In line with this observation, we showed here that cohoused WT and Card9 À/À mice show similar disease susceptibility to acute colitis and colon cancer. However, in a recent study (Bergmann et al., 2017) , the authors found a slight reduction in tumor size in co-housed Card9 À/À mice at a later time point.
They demonstrated the impaired production of IL-1b in Card9 À/À mice and mechanistically reasoned that IL-1b supports tumor-promoting activity of group 3 innate lymphoid cells through IL-22 expression. Though these studies demonstrated pathogenic effects of CARD9-mediated IL-1b production, the beneficial effects of the other major inflammasome-dependent cytokine, IL-18, was apparently normalized by prolonged cohousing of Card9 À/À mice. In summary, our study demonstrates that commensal gut fungi are critical for protection from colitis and CRC, while anaerobic bacteria promote disease pathogenesis. Fungi signal via SYK-CARD9 axis to promote inflammasome assembly, and subsequent IL-18 maturation protects against colitis and colon cancer and promotes anti-tumorigenic T cell responses. Therefore, promoting healthy gut mycobiota could provide protection from IBD and CRC.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
DECLARATION OF INTERESTS
Quantitative Real-Time PCR RNA was isolated by using RNeasy kit (Sigma-Aldrich) as per manufacturer's instructions and converted into cDNA as previously described . Gene expression was assessed by using the 2 3 SYBR Green master mix as per the manufacturer's instructions (Applied Biosystems). Sequences for quantitative RT-PCR (qRT-PCR) primers are listed in Table S1 . qRT-PCR data were analyzed by the 2 -DDCT method, with b-actin as the housekeeping gene.
Microbiota sequencing
Genomic DNA from feces was extracted by bead beating followed by QiAMP DNA stool Mini Kit (QIAGEN, Valencia, CA). Sequencing libraries were generated from 1-50 ng genomic DNA by using the Bioo Scientific NEXTflex 16 s V1-V3 amplicon protocol. This method prepares amplicon libraries that span the hypervariable domains (V1-V3) of microbial 16 s ribosomal RNA genes. The protocol uses a two-step amplification protocol. The first PCR step targets the V1-V3 domains, then the second PCR integrates adaptor and index sequences that are compatible with paired-end sequencing on the Illumina MiSeq platform. Sequencing libraries generated from microbial 16 s ribosomal DNA were quality assessed for insert size distribution using an Agilent Bioanalyzer and quantified by fluorescence assay (picogreen) before pooling in equimolar ratios. Samples were pooled and sequenced using an Illumina MiSeq system using paired-end 300 base sequencing chemistries. Between 200,000 and 1 million total reads ($120 -600 Mb per sample) were generated. The Illumina pair-ended reads with low-quality bases were trimmed to reduce sequencing or PCR errors at this step. The sequences were subsequently assembled into contigs. The contigs with ambiguous bases, chimeric sequences or incorrect assembly size were excluded from downstream analysis. The open reference OTU picking strategy as implemented in QIIME (Caporaso et al., 2010) was used to identify the OTUs from the assembled contigs. Briefly, the contigs were clustered against the Greengene 16S rRNA database (DeSantis et al., 2006) . The contigs that failed to hit in the reference sequence were excluded from downstream analysis. Taxonomy of each OTU was assigned by comparing with the Greengene reference OTUs. The final result contained an OTU matrix detailing the information about the number of sequences in each OTUs and their taxonomy assignment. Similar work flow was utilized to characterize fungal diversity with NEXTflex 18 s ITS Amplicon-Seq Kit and UNITE fungal 18S ITS database (Kõ ljalg et al., 2013) . Kruskal-Wallis non-parametric tests was used to test the significance of the difference of diversity. The linear discriminant analysis (LDA) effect size (LEfSe) method was used to test the significant difference of relative abundance of taxa among groups (Segata et al., 2011) .
QUANTIFICATION AND STATISTICAL ANALYSIS
Data on changes in body weight were analyzed by two-way ANOVA, followed by the Holm-Sidak post hoc test. Statistical significance for other datasets was determined by parametric or non-parametric tests when appropriate and is indicated in the respective figure legends. The number of repeats for each experiment is also indicated in the respective figure legends. N in the figure legends indicates the number of mice used in the experiments. p < 0.05 was considered significant, and is represented as *p < 0.05, **p < 0.01, ***p < 0.001, and NS: not significant.
